Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
Diabetes Care. 2010 Apr;33(4):742-4. doi: 10.2337/dc09-1600. Epub 2010 Jan 12.
To measure ghrelin and energy intake in the laboratory after pioglitazone treatment.
This was a parallel, three-arm study with 51 obese diabetic subjects randomized to either 1) pioglitazone plus a portion-controlled diet (Pio+PC), 2) pioglitazone plus American Diabetes Association (ADA) dietary advice (Pio+ADA), or 3) metformin plus ADA advice (Met+ADA). Energy intake and the suppressive response of a meal on ghrelin were measured at weeks 0 and 16. Mixed models tested if changes from week 0 to 16 differed by group.
The Pio+ADA group had a significantly larger increase (P < 0.05) in energy intake ([adjusted means +/- SE] 207 +/- 53 kcal) compared with the Pio+PC (50 +/- 46 kcal) and Met+ADA (52 +/- 49 kcal) groups. Change in restraint and disinhibition (variables associated with eating behavior) mediated weight change. Ghrelin suppression increased in the Pio+ADA group, which gained weight.
A portion-controlled diet attenuated the increase in energy intake after pioglitazone. Ghrelin responded to weight change not pioglitazone exposure.
在吡格列酮治疗后，于实验室测量ghrelin 和能量摄入。
这是一项平行的三臂研究，共有 51 例肥胖的糖尿病患者随机分为三组：1）吡格列酮+饮食控制（Pio+PC），2）吡格列酮+美国糖尿病协会（ADA）饮食建议（Pio+ADA），或 3）二甲双胍+ADA 建议（Met+ADA）。在第 0 周和第 16 周，分别测量能量摄入和进食对 ghrelin 的抑制反应。混合模型检验从第 0 周到第 16 周的变化是否因组而异。
与 Pio+PC（50±46 千卡）和 Met+ADA（52±49 千卡）组相比，Pio+ADA 组的能量摄入增加（[调整后的均值±SE]207±53 千卡）显著更大（P<0.05）。约束和抑制的变化（与饮食行为相关的变量）介导了体重变化。ghrelin 的抑制作用在 Pio+ADA 组增加，而该组体重增加。
饮食控制可以减弱吡格列酮治疗后能量摄入的增加。ghrelin 对体重变化而不是吡格列酮暴露有反应。
